Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
'We expect to get the approval in the next few weeks,' says Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL).
India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi.
Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd said on Wednesday it will acquire the pharmaceutical services business of US-based Solutia Inc for $74.5 million.
There is no one way to describe the 12 months that have gone by since India reported its first Covid-positive case on January 30, 2020.
Pune-based Bilcare Ltd has acquired a US-based pharmaceutical service and packaging company ProClinical Inc.
Patheon Inc, the pharmaceutical service provider, is looking for Senior Scientists and Formulation Development Managers.
Analysts are eyeing bigger launches that will positively impact company's fortunes.
No Indian auto brand (including Tata or Mahindra) is well-known globally.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances